Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH001 combined with Toripalimab in advanced NSCLC and HCC
NCT05212922Phase 2Withdrawn
- Sponsor
- Eucure Biopharma
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of YH001 in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by Eucure Biopharma. Planned start Jun 2023; status: withdrawn.
02
Drugs
YH001
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05212922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212922.